ð ç« æ«éèš
- Malaria: 5 species (P. falciparum most severe; vivax/ovale relapse via hypnozoites; knowlesi zoonotic SE Asia)
- Anopheles mosquito vector; sporozoite â hepatocyte â merozoite â RBC â fever paroxysm
- Classic triad: cold/hot/sweating stages; periodicity by species
- Severe malaria: cerebral, anemia, AKI, ARDS, acidosis, hypoglycemia, shock, hyperparasitemia
- Diagnosis: thick + thin Giemsa smears (q12h à 3 if neg), RDTs (HRP-2 + pLDH), PCR
- Uncomplicated Tx: ACT (artemether-lumefantrine first-line)
- Severe Tx: IV artesunate drug of choice (AQUAMAT trial); no steroid; ICU + supportive
- Radical cure P. vivax/ovale: primaquine 14d or tafenoquine 300 mg à 1; G6PD test required; pregnancy contraindicated
- Prophylaxis: Malarone, doxycycline, mefloquine, chloroquine (sensitive areas), tafenoquine
- Vaccines: RTS,S/AS01 (2021) + R21/Matrix-M (2023, mass rollout 2024) â game changers for Africa
- Resistance: artemisinin (kelch13) SE Asia + emerging Africa; chloroquine widespread P. falciparum
- Mosquirix RTS,S 4-dose 36% efficacy; R21 75% efficacy (more effective + cheaper)
- 95% global malaria mortality in Africa; 80% in children < 5
- ç§é«åž« hint: returning traveler + fever â ç«å³ malaria smear + RDT; severe â IV artesunate without delay